Literature DB >> 12792499

FTY720 reduces T-cell recruitment into murine intestinal allograft and prevents activation of graft-infiltrating cells.

Takuya Kimura1, Toshimichi Hasegawa, Hiroshi Nakai, Tatsuo Azuma, Noriaki Usui, Takashi Sasaki, Akira Okada.   

Abstract

BACKGROUND: Effective immunosuppression is a critical determinant of graft survival in small-bowel transplantation (SBTx). The present study was designed to determine the potency of FTY720, a newly synthesized immunosuppressant, in rat SBTx and examine the phenotype of graft-infiltrating cells to evaluate its effect on intestinal allografts.
MATERIALS AND METHODS: A segment of intestine of Dark Agouti rats was transplanted heterotopically into Lewis rats. The recipients were treated with or without oral FTY720 at a dose of 1 mg/kg per day. Six days after surgery, peripheral blood lymphocytes and lymphocytes from the mesenteric lymph nodes, Peyer's patches, intraepithelial site, and lamina propria of the intestinal allograft were isolated. After the number of lymphocytes in each site was counted, the lymphocyte subpopulations in the intestinal allograft were evaluated by means of a FACScan flow cytometer using several monoclonal antibodies.
RESULTS: FTY720 treatment significantly prolonged recipient survival and strongly inhibited rejection histologically in comparison with control rats. FTY720 immunosuppression resulted in a marked reduction of lymphocyte number in the graft epithelium and lamina propria and the proportion of CD8+ and CD25+ cells. FTY720 also significantly decreased T-cell receptors and increased B cells in the graft Peyer's patches.
CONCLUSION: FTY720 promoted long-term SBTx recipient survival and maintained the architecture of intestinal allografts. FTY720 immunosuppression may be associated with a reduction of T-cell recruitment subsequent to the redistribution of lymphocyte subpopulations to control the proliferation and activation of graft-infiltrating cells in intestinal allografts.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12792499     DOI: 10.1097/01.TP.0000058816.13525.92

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease.

Authors:  S-K Jo; A Bajwa; A S Awad; K R Lynch; M D Okusa
Journal:  Kidney Int       Date:  2008-03-05       Impact factor: 10.612

2.  Local delivery of FTY720 accelerates cranial allograft incorporation and bone formation.

Authors:  Cynthia Huang; Anusuya Das; Daniel Barker; Sunil Tholpady; Tiffany Wang; Quanjun Cui; Roy Ogle; Edward Botchwey
Journal:  Cell Tissue Res       Date:  2011-08-24       Impact factor: 5.249

3.  Inhibition of donor-derived T cells trafficking into target organs by FTY720 during acute graft-versus-host disease in small bowel transplantation.

Authors:  J Song; T Ito; C Matsuda; G Miao; M Tanemura; T Nishida; M Nozawa; H Matsuda; Y Sawa
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

Review 4.  Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system.

Authors:  Mirjam Schuchardt; Markus Tölle; Jasmin Prüfer; Markus van der Giet
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

5.  Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants.

Authors:  Reza Soleimani; Elke Heytens; Kutluk Oktay
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

6.  FTY720 Suppresses Liver Tumor Growth and Metastasis by Reducing Circulating Regulating T Cells and Enhancing the Anti-Tumor Effect of Rapamycin.

Authors:  Chang Xian Li; Xin Xiang Yang; Hong Wei Wang; Xiang Cheng Li; Kevin Tak-Pan Ng; Chung Mau Lo; Kwan Man
Journal:  Onco Targets Ther       Date:  2020-05-26       Impact factor: 4.147

7.  FTY720 Regulates Mitochondria Biogenesis in Dendritic Cells to Prevent Kidney Ischemic Reperfusion Injury.

Authors:  Thomas V Rousselle; Canan Kuscu; Cem Kuscu; Kailo Schlegel; LiPing Huang; Maria Namwanje; James D Eason; Liza Makowski; Daniel Maluf; Valeria Mas; Amandeep Bajwa
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.